Federal Court finds PMPRB reasonably concluded Galderma's patent claiming 0.3% adapalene "pertained to" 0.1% adapalene DIFFERIN | Smart & Biggar
On January 11, 2024, the Federal Court released its decision concluding that the Patented Medicine Prices Review Board (PMPRB or Board) was reasonable in its redetermination that the...